Condition

Metastatic Renal Cell Carcinoma

ClinicalTrials.gov condition label

Clinical trials17

Recruiting5

Common interventions25

Lead sponsors shown13

Clinical trials

17 shown

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT StudyNCT07405086 · 2026-06-08

Measuring Oncological Value of Exercise and StatinNCT05796973 · 2023-03-31

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · 2022-04-29

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 · 2022-03-31

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialNCT04693377 · 2021-03-16

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12

ACTIVE_NOT_RECRUITING

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)NCT05259319 · 2022-12-05

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22

ACTIVE_NOT_RECRUITING

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246 · 2021-08-05

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNCT04140526 · 2020-09-16

ACTIVE_NOT_RECRUITING

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint BlockadeNCT03474497 · 2019-05-20

ACTIVE_NOT_RECRUITING

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsNCT03682289 · 2019-01-17

ACTIVE_NOT_RECRUITING

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyNCT03589339 · 2019-01-16

ACTIVE_NOT_RECRUITING

INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological CancersNCT03071328 · 2018-01-08

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495 · 2015-06-26

RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)NCT02026960 · 2014-03-01

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid TumorsNCT01482156 · 2012-01-01

Common interventions

Leading sponsors

M.D. Anderson Cancer Center3 Duke University2 NRG Oncology2 Centre Georges Francois Leclerc1 Mayo Clinic1 Megan Daly, MD1 Nanobiotix1 National Cancer Institute (NCI)1 Novartis Pharmaceuticals1 OHSU Knight Cancer Institute1 OncoC4, Inc.1 Rahul Aggarwal1 Tampere University Hospital1

Trial status mix

ACTIVE_NOT_RECRUITING6

RECRUITING5

TERMINATED3

COMPLETED2

UNKNOWN1

Phase mix

PHASE19

PHASE24

PHASE33

NA2

EARLY_PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.